ardiac drugs: Seldane (terfenadine),
Propulsid (cisapride), and Nizoral (ketoconazole), and ChanTest pioneered
the development of functional, cell-based ion channel testing as a means to
predict cardiac side effects produced by non-cardiac drugs. Such testing is
now a standard component of regulatory submissions prior to the approval of
drugs for use in humans. ChanTest is committed to innovation, and is
leading the next major advance in ion channel research and services with a
$10 million program to develop the world's most extensive library or
catalog of ion channels. ChanTest's expert electrophysiologists fully
validate the ion channels for interrogation with functional,
pharmacological, and biochemical assays.
The A/C/T Assays and Cellular Targets conference and exhibition takes
place September 24-26, 2008 at the Marriott San Diego Hotel & Marina in
California.
About ChanTest
The preeminent ion channel services company, ChanTest serves its drug
discovery and development customers with GLP safety and automated screening
assays using its library of ion channel-expressing cell lines - the most
comprehensive in the world. Since its inception in 1998, ChanTest has
tested more than 18,000 compounds for more than 250 global pharmaceutical
and biotech companies - helping them to achieve their drug safety and
discovery goals. ChanTest works in partnership with customers to speed the
drug-development process, save time and money, and ultimately -- to help
make better, safer drugs. Because of ChanTest's seminal role in this field,
along with the company's uncompromising commitment to quality, ChanTest was
named "most trusted fee-for-service provider" for ion channel screening in
the HTStec Ion Channel Trends Survey for two years in a row. ChanTest is
based in Cleveland, Ohio. For more information, please visit
http://www.chantest.com.
'/>"/>SOURCE ChanTest Copyright©2008 PR Newswire. All rights reserved | |
Page: 1 2 Related biology technology :1.
ChanTest to Highlight the Worlds Largest Catalog of Ion Channel-Expressing Cell Lines and Discovery Services at Ion Channel Targets, Booth 52.
ChanTest Launches New Business to Provide Validated Ion Channel Expressing Cell Lines to the Research Community3.
ChanTest to Highlight the Worlds Largest Catalog of Ion Channel-Expressing Cell Lines and Discovery Services at Drug Discovery Technology, Booth 8394.
ChanTest Launches Redesigned Web Site5.
ChanTest to Highlight Most-Comprehensive Range of Ion Channel Profiling Screens and Consultation Services at 14th Annual SBS Conference, Booth 11046.
ChanTest to Highlight Expanded Ion Channel Testing Services for Preclinical Safety at ToxExpo, Including the Worlds Largest Catalog of Validated Ion Channels, Booth 25047.
Epeius Biotechnologies Lead Product, Rexin-G for Metastatic Cancer, Aptly Highlighted by National Cancer Institute Journal8.
New Study by BioTrends Highlights Anemia Practice Patterns According to Anemia Managers in Both Dialysis Units and CKD Clinics/Offices9.
Neuralstem Reports Second Quarter Financial Results and Highlights10.
DOE JGI Director Eddy Rubin highlights the genomics of plant-based biofuels in the journal Nature11.
Informed Medical Communications Highlights Opportunity in Revised PhRMA Code